11211 Sorrento Valley Road
About Expedeon Inc.SYGNIS and Expedeon share a vision of innovation and service by providing cutting edge, patented genomics and proteomics tools to the scientific community. By joining SYGNIS's genomic R&D expertise with Expedeon's proteomic tools and consumables Expedeon will be able to offer a wide variety of innovative products across workflows covering single cell genomics, large scale proteomics and everything in between.
Tweets by Expedeon
11 articles with Expedeon Inc.
Expedeon AG licenses Lightning-Link® Rapid Biotinylation technology to Cell Guidance Systems in supply agreement
License allows Cell Guidance Systems to use Lightning-Link® in manufacture of TRIFic™ exome detection immunoassay kits
74% increase in revenues to € 9.3 million for the first nine months of 2018 versus same period in 2017
Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology
Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products
Expedeon AG signs supply agreement with Reszon Diagnostics for proprietary colloidal gold technology
Expedeon’s proprietary colloidal gold to be used for manufacturing of diagnostic lateral flow assays
Expedeon AG said today that the management is not aware of any change in the operational or strategic position of the Company which would justify the recent movement in the share price.
Expedeon AG today announced the signing of a licence and supply agreement for its colloidal gold with South Korea-based PaxGenBio, a privately held, independent developer and supplier of rapid, highly sensitive multiplex diagnostic kits.
Expedeon AG secures GBP 5 million in debt financing
Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company will present at the following investor conferences.
Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced the introduction of five new Alexa Fluor® labels to its range of Lightning-Link® antibody labelling kits.
Expedeon AG (formerly SYGNIS AG) reports financial results for the first six months of 2018 and successful execution of name change
Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today reported results for the second quarter of 2018 and six-month period ended 30 June 2018. In addition, the Company has officially completed the change of name to Expedeon AG from SYGNIS AG.
Expedeon Inc Release: TruePrime Liquid Biopsy Kit Is A Ready To Use Amplification Kit For Cell-Free DNA